Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary
The DOI matches its Crossref record; 299 of the 300 references it cites were found in a registry or an index.
Abstract
Abbreviations: A1C = hemoglobin A1C; AACE = American Association of Clinical Endocrinologists; ABCD = adiposity-based chronic disease; ACCORD = Action to Control Cardiovascular Risk in Diabetes; ACCORD BP = Action to Control Cardiovascular Risk in Diabetes Blood Pressure; ACE = American College of Endocrinology; ACEI = angiotensin-converting enzyme inhibitor; AGI = alpha-glucosidase inhibitor; apo B = apolipoprotein B; ARB = angiotensin II receptor blocker; ASCVD = atherosclerotic cardiovascular disease; BAS = bile acid sequestrant; BMI = body mass index; BP = blood pressure; CCB = calcium channel blocker; CGM = continuous glucose monitoring; CHD = coronary heart disease; CKD = chronic kidney disease; DKA = diabetic ketoacidosis; DPP4 = dipeptidyl peptidase 4; eGFR = estimated glomerular filtration rate; EPA = eicosapentaenoic acid; ER = extended release; FDA = Food and Drug Administration; GLP1 = glucagon-like peptide 1; HDL-C = high-density-lipoprotein cholesterol; HeFH = heterozygous familial hypercholesterolemia; LDL-C = low-density-lipoprotein cholesterol; LDL-P = low-density-lipoprotein particle; Look AHEAD = Look Action for Health in Diabetes; NPH = neutral protamine Hagedorn; OSA = obstructive sleep apnea; PCSK9 = proprotein convertase subtilisin-kexin type 9 serine protease; RCT = randomized controlled trial; SU = sulfonylurea; SGLT2 = sodium-glucose cotransporter 2; SMBG = self-monitoring of blood glucose; T2D = type 2 diabetes; TZD = thiazolidinedione.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Epidemiologic evidence shows a continuous relationship between A1C and CVD and all-cause mortality.72”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [72]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Cited by
Items 201–300 of 610
Extending our understanding of exenatide: a rare case of angio-oedema
Mahfooz, F., Aylor, K., Mathew, J., & Reichmuth, M. (2021) · BMJ Case Reports · doi:10.1136/bcr-2020-235663 · Cited by 9
Whitehouse, C. R., Akyirem, S., Petoskey, C., Huang, S., Wischik, D. L., Batten, J., & Whittemore, R. (2024) · The Science of Diabetes Self-Management and Care · doi:10.1177/26350106241232649 · Cited by 11
Alqifari, S. F., Komi, O. A., Esmail, A., Alkhawami, K., Yousri, S., Muqresh, M. A., Alharbi, N., Khojah, A. A. A., Aljabri, A. M., Allahham, A., et al. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i3.331 · Cited by 11
Elsherif, I., Jammah, A. A., Ibrahim, A. R., Alawadi, F., Sadek, I. S., Rahman, A. M., Sharify, G. E., AlFeky, A., Aldossari, K. K., Roushdy, E., et al. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.06.003 · Cited by 11
Triadisti, N., Elya, B., Hanafi, M., Hashim, N. M., & Illahi, A. D. (2025) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2025.215871 · Cited by 11
“…T2DM in people at high risk, in pre-diabetic conditions, and in stage 1 and stage 2 diabetes; they are also combined with other T2DM therapies [9–11]. α-Glucosidase inhibitors can be given to individuals with kidney disease, and this makes them a suitable therapy for people living with diabetes…”
Cowart, K., Updike, W. H., & Pathak, R. (2021) · Clinical Diabetes · doi:10.2337/cd20-0080 · Cited by 11
Hu, G., Pan, Y., Wang, M., Meng, X., Jiang, Y., Li, Z., Li, H., Wang, Y., & Wang, Y. (2021) · Biomedicines · doi:10.3390/biomedicines9121947 · Cited by 11
The Transcultural Diabetes Nutrition Algorithm: A Middle Eastern Version
Hamdy, O., Sifri, S. A., Hassanein, M. M., Dawish, M. A. A., Aldahash, R., Alawadi, F., Jarrah, N. S., Ballout, H. A., Hegazi, R. A. F., Amin, A., et al. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.899393 · Cited by 13
“While dyslipidemia for people with diabetes is defined in terms of triglycerides and high-densitylipoprotein cholesterol (HDL-C) levels and a procoagulant and pro-inflammatory milieu (31), the WHO uses a single criterion, i.”
BackgroundInfluentialSelf-citationPractical Guidance on Basal Insulin Initiation and Titration in Asia: A Delphi-Based Consensus
Chan, S. P., Aamir, A. H., Bee, Y. M., Deerochanawong, C., Paz-Pacheco, E. T., Tiu, F., Foo, S. H., Tan, K. E. K., Le, T. Q., Saraswati, M. R., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01286-0 · Cited by 14
Drivers of medicalization in the Canadian Adult Obesity Clinical Practice Guidelines
Bombak, A. E., Adams, L., & Thille, P. (2022) · Canadian Journal of Public Health · doi:10.17269/s41997-022-00662-4 · Cited by 14
“Their Consensus Statement on type 2 diabetes management (Garber et al. 2020), which featured increasingly industry-aligned recommendations, included 15 of 19 authors with industry ties.”
BackgroundUnexplained Residual Risk In Type 2 Diabetes: How Big Is The Problem?
Neppala, S., Rajan, J., Yang, E., & DeFronzo, R. A. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02055-0 · Cited by 12
Self-citationLong-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials
Urquhart, S., & Willis, S. (2020) · JAAPA · doi:10.1097/01.jaa.0000669452.63883.45 · Cited by 12
Insight into the role of PCSK9 in glucose metabolism
Xu, J., Wang, T., Shu, H., Shi, S., Tao, L., & Li, J. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117444 · Cited by 11
The effect and mechanism of liraglutide on the biological functions of BMSCs in diabetic patients
Wang, Y., Sun, Y., Yang, B., Li, J., & Liang, C. (2024) · Oral Diseases · doi:10.1111/odi.14931 · Cited by 11
Haluzík, M., Taybani, Z. J., Araszkiewicz, A., Cerghizan, A., Mankovsky, B., Zuhdi, A., & Malecki, M. T. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01610-w · Cited by 12
“This approach may help decrease treatment complexity and burden leading to optimal glycaemic control and enhanced treatment adherence [4, 5, 9, 49].”
BackgroundDeveloping a Protocol for Management of Euglycemic Diabetic Ketoacidosis
Cardona, Z., Friedman, J. G., Kamal, N., Oakes, D. J., Wallia, A., Aleppo, G., Brown, S., Makowski, C. T., Ritter, K., & Szmuilowicz, E. D. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01604-3 · Cited by 15
Grazhdanski, G., Vasilev, V., Vassileva, S., Taskov, D., Antova, I., Koychev, I. K., & Boytcheva, S. (2025) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2025.104906 · Cited by 23
Alkhatib, N. S., Almutairi, A. R., Alkhezi, O. S., Alfayez, O. M., Yami, M. S. A., & Almohammed, O. A. (2022) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2022.01.018 · Cited by 11
“These two targets were recommended by the American Diabetes Association (ADA) (American Diabetes Association, 2021) and the American Association of Clinical Endocrinologists (AACE) (Garber et al., 2020).”
Flash glucose monitoring system in special situations
Rigon, F., Ronsoni, M. F., Vianna, A. G. D., Schiavon, L. D. L., Hohl, A., & van de Sande‐Lee, S. (2022) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000479 · Cited by 15
An Update on Semaglutide Research: A Bibliometric Analysis and a Literature Review
Dagli, N., Kumar, S., Ahmad, R., Narwaria, M., & Haque, M. (2023) · Cureus · doi:10.7759/cureus.46510 · Cited by 16
“, 2020 [34] Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary Endocrine Practice 343 This document represents the summary of type 2 diabetes management proposed by the Ame…”
BackgroundSher, E. K., Džidić-Krivić, A., Karahmet, A., Beća-Zećo, M., Farhat, E. K., Softič, A., & Sher, F. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102901 · Cited by 29
Nguyen, J. V., Roseberry, S., Rivas, J. A., & Cauthon, K. A. B. (2021) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2021.112 · Cited by 10
Current State and Principles of Basal Insulin Therapy in Type 2 Diabetes
Vargas‐Uricoechea, H. (2022) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4660 · Cited by 13
“In the clinical setting, it is sometimes difficult to define the right moment when BIs management should be considered in individuals with T2DM (who do not achieve metabolic control); different international organizations make different recommendations in this regard (Table 1) [26-28].”
BackgroundCox, E. J., Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2020) · US Endocrinology · doi:10.17925/use.2020.16.2.80 · Cited by 10
Degefa, B. D., Nardos, A., Abdela, J., Terefe, L., Arega, M., Yilma, T., & Tesfaye, T. (2023) · Journal of Experimental Pharmacology · doi:10.2147/jep.s437991 · Cited by 12
Alimentação whole-food plant-based e saúde no contexto da medicina do estilo de vida
Smirmaul, B. P. C. (2023) · Brazilian Journal of Lifestyle Medicine = Revista Brasileira de Medicina do Estilo de Vida · doi:10.61661/bjlm.2023.v2.86 · Cited by 9
Hong, T., Su, Q., Li, X., Shan, Z., Chen, L., Peng, Y., Chen, L., Yan, L., Bao, Y., Lyu, Z., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3416 · Cited by 11
Anderson, J. E., Gavin, J. R., Kruger, D. F., & Miller, E. M. (2022) · Clinical Diabetes · doi:10.2337/cd22-0020 · Cited by 10
Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes
Heller, S. R., Raposo, J. F., Tofé, S., Hanif, W., Schroner, Z., Down, S., & Blevins, T. (2022) · Clinical Diabetes · doi:10.2337/cd22-0016 · Cited by 9
“At 100 years since its discovery, insulin continues to play a key role for glycemic management, as evidenced by international guideline recommendations for basal insulin initiation in people with type 2 diabetes (1,2,4).”
BackgroundHermanns, N., Ehrmann, D., Finke-Gröne, K., Roos, T., Freckmann, G., & Kulzer, B. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221148756 · Cited by 9
Salamah, H. M., Marey, A., Elsayed, E., Hasan, M. T., Mahmoud, A., Abualkhair, K. A., Abo‐elnour, D. E., Abdelhaleem, I. A., & Abd‐ElGawad, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-46274-x · Cited by 10
Singh, A. K., Misra, A., Das, A. K., Behl, A., Srivastava, A., Paneerselvam, A., Chidambaram, B., Saboo, B., Sethi, B. K., Makkar, B. M., et al. (2023) · Journal of the Association of Physicians of India · doi:10.59556/japi.71.0422 · Cited by 12
“The Korean Diabetes Association (KDA) 64 in 2021 and the consensus statement by the American Association of Clinical Endocrinologists (AACE) 65 and the American College of Endocrinology in 2020 recommend SGLT2i as initial therapy for individuals with T2D with or at high-risk atherosclerotic cardiovascular disease (ASC…”
Odetayo, A. F., Abdulrahim, H. A., Yusuf, A. M., Aromokhame, W. O., Olaitan, A. M., Ugoji, M. C., Hamed, M. A., & Olayaki, L. A. (2024) · Reproductive Sciences · doi:10.1007/s43032-024-01708-3 · Cited by 9
“Hence, the Comprehensive Type 2 Diabetes Management algorithm recommends combining metformin with other established drugs [18].”
Dril, E. V., Allison, M., & Schumacher, C. (2022) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2022.100163 · Cited by 11
Wancewicz, B., Zhu, Y., Fenske, R. J., Weeks, A. M., Wenger, K., Pabich, S., Daniels, M., Punt, M., Nall, R., Peter, D. C., et al. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001493 · Cited by 10
“5 – 8%, depending on age and comorbidities (Qaseem et al., 2018; Garber et al., 2020; American Diabetes Association Professional Practice Committee, 2021).”
BackgroundRondanelli, M., Barrile, G. C., Cavioni, A., Donati, P., Genovese, E., Mansueto, F., Mazzola, G., Patelli, Z., Pirola, M., Razza, C., et al. (2023) · Nutrients · doi:10.3390/nu15234943 · Cited by 11
Sassenrath, K., Phillips, B. B., & Stone, R. H. (2021) · Journal of Pharmacy Practice · doi:10.1177/08971900211010678 · Cited by 9
“The 2021 ADADiabetes Standards of Care and the 2020 American Association of Clinical Endocrinology recommendGLP-1 RAs in combinationwith oral agents and/or basal insulin, but there are no specific recommendations regarding the use of GLP-1 RAs for patients receiving MDII regimens, defined as intermediate or long-actin…”
BackgroundKirley, K., Khan, T., Aquino, G. C., Brown, A. R., Meier, S., Chambers, N. A., & O’Connell, C. (2021) · JAMIA Open · doi:10.1093/jamiaopen/ooab101 · Cited by 10
Shubrook, J. H., Pak, J., & DAILEY, G. E. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01405-y · Cited by 9
Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides
Pareek, M., Mason, R. P., & Bhatt, D. L. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1954158 · Cited by 8
“Endocrinologists (AACE)/American College of Endocrinology (ACE) [109].”
Cheung, J. T. K., Yang, A., Wu, H., Lau, E. S. H., Kong, A. P. S., Ronald, C. W., Luk, A. O. Y., Chan, J. C. N., & Chow, E. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3711 · Cited by 10
“3 However, the majority of patients with diabetes did not have cardiovascular ‐ renal disease in whom optimal glycaemic control remained an important strategy for long ‐ term organ protection.”
BackgroundAs, A., Шохин, И. Е., Rogozhina, E. A., Геннадьевна, Б. Т., Nevretdinova, M. E., Bely, P. A., Zaslavskaya, K. Y., Shcherbakova, V. S., Куркин, Д. В., Koryanova, K. N., et al. (2024) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2023-11-4-324-346 · Cited by 13
Zhang, Q.-M., Fan, Y., Liu, X., Zhang, M., Zhang, J., Du, Q., Kang, L., & Chen, L. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01661-z · Cited by 9
“Therefore, comprehensive management is needed in people with T2D to lower blood pressure, lipid levels and body weight through lifestyle modifications and medications in order to reduce the risk of cardiovascular morbidity and mortality [17].”
Bravo-García, A. P., Reddy, A. J., Radford, B. E., Hawley, J. A., & Parr, E. B. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103157 · Cited by 9
Morales, J., Kuritzky, L., Lavernia, F., & Santiago, M. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1857603 · Cited by 8
Chawla, R., Mukherjee, J. J., Chawla, M. S., Kanungo, A. K., Shunmugavelu, M., & Das, A. K. (2021) · Medical Sciences · doi:10.3390/medsci9020038 · Cited by 10
“The AACE 2020 guidelines prefer RAIAs over short-acting RHIs for bolus insulin therapy [68].”
BackgroundMethodInfluentialDharmalingam, M., Das, R., Jain, S. K., Gupta, S., Gupta, M., Kudrigikar, V., Bachani, D., Mehta, S. C., & Joglekar, S. J. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01294-0 · Cited by 9
Time in suboptimal glycemic control over 10 years for patients newly diagnosed with type 2 diabetes
An, J., Nichols, G. A., Qian, L., Harrison, T. N., Li, Z., Munis, M. A., Wei, R. X., Weiss, T., Rajpathak, S. N., & Reynolds, K. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107607 · Cited by 9
Blonde, L., Patel, C. A., Wu, B., Chen, Y., Pericone, C. D., & Bookhart, B. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01549-x · Cited by 8
Self-citationAspirin and Statin Use and the Risk of Gallbladder Cancer
Prasai, K., Tella, S. H., Yadav, S., Kommalapati, A., Mara, K. C., Mady, M., Hassan, M. A. M., Wongjarupong, N., Rodríguez-Payan, N., Borad, M. J., et al. (2021) · Cancers · doi:10.3390/cancers13051186 · Cited by 8
“It is possible that a considerable proportion of patients with these conditions will be on aspirin and statin medications, which might have potentially confounded the results [34].”
BackgroundEfficacy and Safety of Naproxen for Acute Pain
Weisman, S. R. (2020) · The Journal of Family Practice · doi:10.12788/jfp.0064 · Cited by 10
Alguwaihes, A. M. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01092-0 · Cited by 9
Kim, K., Hong, S., Han, K., & Park, C. (2022) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2022.11.1.73 · Cited by 8
Sleep habits in the pathogenesis and management of diabesity
Rasmussen, C. H., Chun Kwan, O., Chan, W. S., Magkos, F., & Kong, A. P. S. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70075 · Cited by 9
Kim, Y. K., Hwang, J. G., & Park, M. K. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s302215 · Cited by 8
Franek, E., Gerstein, H. C., Riddle, M. C., Nicolay, C., Hickey, A., Botros, F. T., & Loo, L. S. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14760 · Cited by 9
“5% or less, provided that it can be achieved without adverse events such as hypoglycaemia.(9) Intensive glycaemic control reduces the risk of microvascular complications(8) and there is a growing body of evidence that it also reduces macrovascular events.”
BackgroundWang, S.-H., Shao, W., Jiang, Q., Zheng, X., Shen, Q., Lin, X.-Y., Zhang, Q.-Q., Zhang, L., Shi, X., Wang, W.-G., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01342-9 · Cited by 10
Boye, K. S., Bae, J. P., Thieu, V. T., & Lage, M. J. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01507-0 · Cited by 8
“In these analyses, targets of B 6.5% and \ 8% were informed by expert guidelines and clinical trials [7, 22–24].”
InfluentialIncreasing the complexity of lipoprotein characterization for cardiovascular risk in type 2 diabetes
Guardiola, M., Rehues, P., Amigó, N., Arrieta, F., Botana, M., Gimeno-Orna, J. A., Girona, J., Martínez‐Montoro, J. I., Ortega, E., Pérez, A., et al. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14214 · Cited by 8
Hall, T. L., Dickinson, L. M., Warman, M. K., Oser, T. K., & Oser, S. M. (2024) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000001060 · Cited by 8
“…Specialists, and the National Committee on Quality Assurance recommend CGM to support achievement of glycemic targets and promote use of CGM metrics for diabetes management and care (Battelino et al., 2019; Garber et al., 2020; National Commitee for Quality Assurance, 2021; Peters et al., 2016).”
Bergenstal, R. M., Ásbjörnsdóttir, B., Bari, T. J., Hulkund, S., Winhofer, Y., & Wysham, C. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.0050 · Cited by 11
Recomendaciones para el manejo del riesgo cardiorrenal en el paciente con diabetes mellitus tipo 2
Castillo, G. A., Aroca, G., Buelvas, J., Buitrago, A. F., Carballo-Zárate, V., Cárdenas, J. M., Gómez, E. A., Fériz, K., Lopera, J. M., Enrique Melgarejo, R., et al. (2020) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2020.07.005 · Cited by 12
“…efec-tiva por la fórmula CKD-EPI y la medición de la relación albuminuria/creatinuria, se deben realizar periódicamente en todo paciente diabético El control de los factores de riesgo, como la hipertensión arterial, la dislipidemia y la glu-cemia elevada, es fundamental para evitar la…”
Chan, K., Szeto, C., Lum, C. C., Ng, P., Kong, A. P. S., Lau, K., Leung, J. Y., Lui, S., Mo, K., Mok, F. C.-K., et al. (2020) · Hong Kong Medical Journal · doi:10.12809/hkmj198330 · Cited by 7
Arrieta, F., Pedro‐Botet, J., Iglesias, P., Obaya, J. C., Montánez, L., Maldonado, G. F., Becerra, A., Navarro, J., Perez, J. C., Petrecca, R., et al. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.05.002 · Cited by 22
“La importancia del ejercicio físico ya fue se˜nalada en 1992 por la Sociedad Americana del Corazón ( American Heart Association , AHA) que incluyó a la inactividad física como un factor de RCV, asociándose también con un riesgo aumen-tado de diabetes mellitus tipo 2 (DM2) 9,20,21 .”
BackgroundInfluentialMoulton, M. K., Johnson, B. R., Lavender, D. L., Osae, S. P., Phillips, B. B., Thomas, I., & Stone, R. H. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280211071089 · Cited by 7
Hu, S., Wang, S., Qi, C., Gu, S., Shi, C., Mao, L., & Fan, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.831364 · Cited by 7
Santen, R. J., Nass, R. M., Cunningham, C., Horton, C., & Yue, W. (2022) · Journal of Telemedicine and Telecare · doi:10.1177/1357633x221106041 · Cited by 11
“” For those under the age of 65 years, guidelines from AACE were utilized.(36) Specifically “a hemoglobin A1C of ≤6.”
MethodGLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2022) · Kidney and Dialysis · doi:10.3390/kidneydial2030034 · Cited by 7
Role of oxidative stress in the development of complications in patients with diabetes mellitus
Bykov, J. (2022) · Medical news of the North Caucasus · doi:10.14300/mnnc.2022.17080 · Cited by 7
Zhou, F., Jiang, L., Guo, J., Fan, Y., Pan, Q., Li, T., Sun, X., & Li, P. (2023) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223231161516 · Cited by 7
Sethi, B. K., Sahay, R. K., TIWASKAR, M. H., Negalur, V. B., Dhediya, R., Gaurav, K., Rathod, R., Kotak, B., Dhanaki, G. D., & Shah, S. P. (2023) · Drugs - Real World Outcomes · doi:10.1007/s40801-023-00398-8 · Cited by 9
“According to the American Association of Clinical Endocrinologists, criteria to consider while selecting a suitable agent include glycated hemoglobin (HbA1c) decrease, alteration in body weight, change in blood pressure (BP) and risk of hypoglycaemia [9].”
BackgroundZhang, F., Ji, L., Hong, T., Guo, L., Li, Y., Zhu, Z., Liu, X., Liu, F., Tang, L., Zhang, Y., et al. (2022) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12474 · Cited by 8
Lopes, A. C., Roque, F., Lourenço, O. M., Herdeiro, M. T., & Morgado, M. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2172159 · Cited by 7
“disease with reduced ejection fraction [13].”
Use of continuous glucose monitoring to improve glycemic management: A clinician's guide
Schumacher, C., Isaacs, D. M., Collier, I. A., & Klinkebiel, D. (2020) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1295 · Cited by 7
“The American Association of Clinical Endocrinologists (AACE) recommends that CGM be used in all patients who have severe hypoglycemia, or hypoglycemia unawareness, or whenever indicated in persons with type 1 or type 2 diabetes to assist patients in reaching glycemic goals safely.(5,6) The ADA and AACE also recommend…”
BackgroundBahat, G., Çatıkkaş, N. M., Karan, M. A., & Petrović, M. (2021) · Acta Clinica Belgica · doi:10.1080/17843286.2021.1952379 · Cited by 7
“73 m(2), MF initiation is generally not recommended [36]; however, initial therapy with 500 mg once daily with the evening meal”
BackgroundChanges in diabetes prescription patterns following Affordable Care Act Medicaid expansion
Gemelas, J. C., Marino, M., Valenzuela, S. H., Schmidt, T. D., Suchocki, A., & Huguet, N. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002135 · Cited by 7
“4 However, in the USA, the cost of diabetes medication can be a significant barrier,”
Liu, Y., Ma, W., Fu, H., Zhang, Z., Yin, Y., Wang, Y., Liu, W., Yu, S., & Zhang, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1235639 · Cited by 8
Meyer, J., Dreischmeier, E., Lehmann, M., & Phelan, J. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280221107381 · Cited by 6
“8%) Time since diabetes diagnosis (years)b (n=50) 20 ± 8; (4-42) Weight (kg)b (n=68) 127.”
Liu, J., Su, S., Kuo, F.-C., Li, P., Huang, C., Ho, L.-J., Chen, K.-C., Liu, Y.-C., Lin, C.-P., Cheng, A.-C., et al. (2023) · Medicine · doi:10.1097/md.0000000000033167 · Cited by 6
“[20,21] Updated guidelines from the American Diabetes Association and American Association of Clinical Endocrinologists recommend to consider a combination of GLP-1 RA therapies in T2D with high risks or established atherosclerotic cardiovascular disease, independent on individualized HbA1C target.[4,22] Moreover, bas…”
BackgroundWong, T.-W. (2023) · Clinical Diabetology · doi:10.5603/dk.a2023.0008 · Cited by 6
Ehrhardt, N. M., Aroda, V. R., Galindo, R. J., Peters, A. L., & Shubrook, J. H. (2023) · Clinical Diabetes · doi:10.2337/cd23-0047 · Cited by 6
Krishnan, K., Raman, S., Moses, C. R. A., Rajesh, R. P., Gupta, A., Mudaliar, V., & Vimal, J. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.111034 · Cited by 6
Wang, X., Ma, H., Li, X., Liang, Z., Fonseca, V. A., & Qi, L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15443 · Cited by 6
Alvis‐Guzmán, N., Romero, M., Salcedo‐Mejía, F., Carrasquilla-Sotomayor, M., Gómez, L., Rojas, M. M., Urrego, J. C., Beltrán, C. C., Ruíz, J. E., Velásquez, A., et al. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01245-0 · Cited by 6
“Its importance has been extensively communicated through current national and international clinical guidelines [18, 19].”
BackgroundArabi, S. M., Jazinaki, M. S., Abadi, M. N., Bahrami, L. S., Chambari, M., Bahari, H., & Sahebkar, A. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128306300240522074056 · Cited by 6
Krishnan, A., Schneider, C. V., Arkenau, H., Mauro, E., Forner, A., Butsch, W. S., Walsh, D., & Alqahtani, S. A. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100370 · Cited by 13
“DPP-4Is have weight-neutral effects but reduce cardiovascular risk factors [5,6].”
BackgroundManaging the Burden of Dementia-Related Delusions and Hallucinations
Small (2020) · The Journal of Family Practice · doi:10.12788/jfp.0065 · Cited by 6
Banjara, B., Poudel, N., Garza, K. B., Westrick, S. C., Whitley, H. P., Redden, D. T., & Ngorsuraches, S. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s391719 · Cited by 6
“The American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) developed the comprehensive T2DM management algorithm.(17) A central theme of the AACE/ACE algorithm is patientcentered diabetes therapies, which are also mirrored by the ADA.”
BackgroundSchapiro, D., Juneja, R., Huang, A., Meeks, A., Liu, D., Gelsey, F. T., & Perez‐Nieves, M. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01414-4 · Cited by 7
“These guidelines also recommended the use of insulin in combination with GLP-1RAs if HbA1c is very high ([ 9%), or if PwT2D exhibit symptoms of catabolism suggesting insulin deficiency [9].”
BackgroundResultInfluentialMinasian, V., & Nazari, M. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122114 · Cited by 7
Beshyah, S., Hafidh, K., & Shaikh, T. G. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108389 · Cited by 6
Lan, N. S. R., Burns, K. A., Bell, D. A., & Watts, G. F. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000594 · Cited by 6
Meade, L. T., & Battise, D. M. (2021) · Clinical Diabetes · doi:10.2337/cd20-0094 · Cited by 6
Bae, J. H., Ahn, C. H., Yang, Y., Moon, S. J., Kwak, S. H., Jung, H. S., Park, K. S., & Cho, Y. M. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0274 · Cited by 7
Wood, S. J., Bell, J. S., Magliano, D. J., Shaw, J. E., Cesari, M., & Ilomäki, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.886834 · Cited by 6
Identification of Probucol as a candidate for combination therapy with Metformin for Type 2 diabetes
Guttapadu, R., Korla, K., Safnaz, U. K., Annam, V., Ashok, P., & Chandra, N. R. (2023) · npj Systems Biology and Applications · doi:10.1038/s41540-023-00275-8 · Cited by 6
Ko, S., Kim, H., Shinn, J., Byeon, S., Choi, J., & Kim, H. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13381 · Cited by 6
Liu, X., Li, C., Huo, X., Liu, J., Liu, J., Cao, W., & Zheng, J. (2026) · Scientific Reports · doi:10.1038/s41598-026-36923-2 · Cited by 5
“The health management of T2DM patients can be enhanced by annual CVD risk factor assessments, as stated in the 2020 American Diabetes Association guidelines 10 .”
Cardiovascular Risks With SGLT2 Inhibitors in Clinical Practice Among Patients With Type 2 Diabetes
Su, H., Yang, C., Lee, Y., Su, P., Liu, Y.-C., & Ou, H. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.41765 · Cited by 5
Joshi, N., Baloch, K. M., Rukh, S., Khan, A. M., Muskan, F., Kumari, V., Khan, H., Zeeshan, M., Azam, G., Khalid, S., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002712 · Cited by 6
“Although GLP-1 RAs are neither FDA-approved nor of fi cially recommended in the management of type 1 diabetes [111,112] , off-label use added to insulin might contribute to weight reduction and better glycemic control in a subset.”
Metadata
- Authors
- Garber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., Garvey, W. T., Hirsch, I. B., Jellinger, P. S., McGill, J. B., Mechanick, J. I., Perreault, L., Rosenblit, P. D., Samson, S., & Umpierrez, G. E.
- Affiliations
- Baylor College of Medicine (US)
- Oakland University (US)
- University of California San Diego (US)
- Beth Israel Deaconess Medical Center (US)
- Kaiser Permanente (US)
- Ochsner Health System (US)
- Cedars-Sinai Medical Center (US)
- The University of Texas at San Antonio Health Science Center (US)
- University of Alabama at Birmingham (US)
- University of Washington (US)
- University of Miami (US)
- Washington University in St. Louis (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of Colorado Anschutz (US)
- University of California, Irvine (US)
- Emory University (US)
- ORCID
- Venue
- Endocrine Practice
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 26
- Issue
- 1
- Pages
- 107-139
- ISSN
- 1530-891X (ISSN-L)
- OpenAlex
- W3004838676
- Cited by
- 598
- References
- 300
- Citations by year
- 2026: 21 · 2025: 41 · 2024: 80 · 2023: 104 · 2022: 146 · 2021: 125 · 2020: 81
- FWCI
- 85.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Endocrine Practice (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes management, glycemic control, cardiovascular risk, atherosclerotic cardiovascular disease, chronic kidney disease, diabetic ketoacidosis, obstructive sleep apnea, dyslipidemia, obesity, GLP-1 receptor agonists, SGLT2 inhibitors, insulin therapy, continuous glucose monitoring, self-monitoring of blood glucose
- MeSH terms
- Proprotein Convertase 9, Endocrinologists, Algorithms, Blood Glucose, Diabetes Mellitus, Type 2, Humans, United States, Blood Glucose Self-Monitoring, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.